Ontology highlight
ABSTRACT:
SUBMITTER: Criscitiello C
PROVIDER: S-EPMC7844898 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
Criscitiello Carmen C Morganti Stefania S Curigliano Giuseppe G
Journal of hematology & oncology 20210128 1
Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly described as the "Trojan Horses" of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacitu ...[more]